Endofotonics
Endofotonics is pioneering the development of an AI-enabled platform for in-vivo real-time cancer diagnosis, aiming to improve timely medical interventions. Their mission is to provide real-time early gastrointestinal cancer diagnosis, with the vision to reduce cancer burden through earlier detection. The company was incorporated in 2013 and has achieved several milestones, including raising an angel round in 2014 and a pre-Series A round in 2015. They developed their IMDx lab prototype in 2014, the IMDx probe in 2016, and the SPECTRA IMDx™ system in 2017, establishing a subsidiary in Shanghai, China in the same year. Further development included an engineering prototype in 2018, commencement of clinical trials in 2020, and sales within China in 2021, followed by sales outside China in 2022. Endofotonics has offices in Singapore and Shanghai.
Endofotonics
Endofotonics is pioneering the development of an AI-enabled platform for in-vivo real-time cancer diagnosis, aiming to improve timely medical interventions. Their mission is to provide real-time early gastrointestinal cancer diagnosis, with the vision to reduce cancer burden through earlier detection. The company was incorporated in 2013 and has achieved several milestones, including raising an angel round in 2014 and a pre-Series A round in 2015. They developed their IMDx lab prototype in 2014, the IMDx probe in 2016, and the SPECTRA IMDx™ system in 2017, establishing a subsidiary in Shanghai, China in the same year. Further development included an engineering prototype in 2018, commencement of clinical trials in 2020, and sales within China in 2021, followed by sales outside China in 2022. Endofotonics has offices in Singapore and Shanghai.